BioPorto Announces Interim Results for the First Six Months of 2022

COPENHAGEN, Denmark and BOSTON, Aug. 17, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced interim financial results for the first six months of 2022 and business progress for the second quarter of 2022.

Recent Highlights

• For the six months ending June 30, 2022:
  • Total revenue of DKK 15.0 million / USD 2.2 million, a 23% increase over the prior year
  • Adjusted EBITDA of DKK (32.4) million / USD (4.8) million
  • Cash and cash equivalents of DKK 107.9 million / USD 15.1 million as of June 30, 2022 (DKK 75.0 million / USD 12.0 million as of June 30, 2021)
• For the second quarter ending June 30, 2022:
  • Total revenue of DKK 8.5 million / USD 1.2 million, a 29% increase over the prior year
  • Adjusted EBITDA of DKK (17.1) million / USD (2.5) million
• Achieved targeted enrollment in clinical study supporting FDA De Novo submission for The NGAL Test in the US
• Appointed world-leading nephrologist and NGAL biomarker pioneer, Dr. Prasad Devarajan, as new Senior Medical Director
• Successful implementation of NGAL testing programs was highlighted at the 40th Vincenza Course on AKI & CRRT meeting in Vincenza, Italy – “Meet the Expert” video

Tony Pare, BioPorto’s Chief Executive Officer, said: “I am pleased with our strong second quarter of 2022, a result of disciplined execution on our strategic agenda. We look forward to completing The NGAL Test clinical trial data analysis and related work, and then submitting the De Novo application to the US Food and Drug Administration (FDA). We remain excited about The NGAL Test’s potential impact to assist clinicians in improving outcomes for critical care patients.”

Guidance for 2022 Updated
During the first half of 2022, BioPorto experienced solid sales performance driven by both The NGAL Test and a notable bulk order of antibodies. Based on this, BioPorto increases the upper end of its revenue guidance for the 2022 fiscal year, with a new range of DKK 24 to 27 million. The previous range was DKK 24 to 26 million. BioPorto maintains its 2022 financial guidance for:

• Operating (EBIT) loss of approximately DKK 95 to 100 million
• Adjusted EBITDA loss of approximately DKK 76 to 81 million

Conference Call and Webcast
The Company’s management team will host an online investor presentation on August 17, 2022, at 14:00 Central European Time / 8:00 Eastern Time via HC Andersen Capital. Investors interested in attending the webcast may register at: https://bit.ly/3PkwjX9

A separate analyst call will be held on August 17, 2022, at 16:00 Central European Time / 10:00 Eastern Time, with details as follows:

Denmark: +45 8025 1917
International: +1 201-689-8562
US: +1 877 407 0789
Conference ID: 13732188
Webcast: https://bit.ly/3C342S0

Investor Relations Contacts
Tim Eriksen, EU Investor Relations, Zenith Advisory, +45 4529 0000, [email protected]
Ashley Robinson, US Investor Relations, LifeSci Advisors, +1 617 430 7577, [email protected]

About BioPorto
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company’s flagship product is The NGAL Test, which has been designed to aid in the risk assessment of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality if not identified and treated early. With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The NGAL Test is CE marked and registered in a number of countries worldwide.

BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com.

Forward-looking statement disclaimer
Certain statements in this news release are not historical facts and may be forward-looking statements. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Company’s expectations, intentions and projections regarding its future performance including the Company’s Guidance for 2022; currency exchange rate fluctuations; anticipated events or trends and other matters that are not historical facts, including with respect to the potential FDA clearance, commercialization of The NGAL Test, and the development of future products and new indications; concerns that may arise from additional data, analysis or results obtained during clinical trials; and, the Company’s ability to successfully market both new and existing products. These forward-looking statements, which may use words such as “aim”, “anticipate”, “believe”, “intend”, “estimate”, “expect” and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, and uncertainties that could cause the actual results of operations, financial condition, liquidity, dividend policy and the development of the industry in which the Company’s business operates to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Factors that may impact BioPorto’s success are more fully disclosed in BioPorto’s periodic financial filings, including its Annual Report for 2021, with the Danish Financial Supervisory Authority, particularly under the heading “Risk Factors”.

NOTE – DKK/USD exchange rates used within “Recent Highlights”, above:

• Balance sheet measures: June 30, 2021 = 6.2573 and June 30, 2022 = 7.1620.
• Income statement measures for six months ended: June 30, 2021 = 6.1479 and June 30, 2022 = 6.7864.
• Income statement measures for second quarter ended: June 30, 2021 = 6.1797 and June 30, 2022 = 6.9061.
  

Consolidated Financial Highlights

	2022		2021		2022		2021		2021
	Apr 1 - Jun 30		Apr 1 - Jun 30		Jan 1 - Jun 30		Jan 1 - Jun 30		Jan 1 - Dec 31
DKK million (except where noted)	(Unaudited)		(Unaudited)		(Unaudited)		(Unaudited)
Revenue	8.5		6.6		15.0		12.2		24.3
Gross profit	6.1		4.5		10.0		7.7		15.0
Sales and marketing costs	5.1		2.9		9.1		8.3		17.4
Research and development costs	9.8		7.3		17.8		15.5		30.3
Administrative costs	11.3		8.9		21.4		16.6		32.7
Loss before financial items (EBIT)	(20.1)		(14.5)		(38.4)		(32.7)		(65.3)
Financial items, net	0.8		(0.6)		0.7		0.5		1.4
Loss before tax	(19.4)		(15.2)		(37.7)		(32.2)		(63.8)
Net loss	(17.1)		(13.6)		(34.1)		(29.0)		(57.1)
Comprehensive loss	(17.8)		(13.6)		(34.9)		(29.2)		(58.3)
Non-current assets					16.2		14.2		17.1
Cash and cash equivalents					107.9		75.0		45.5
Current assets					130.7		95.3		64.2
Total assets					146.9		109.5		81.3
Equity					107.9		76.5		46.0
Non-current liabilities					9.4		8.0		10.5
Current liabilities					29.6		25.0		24.8
Total equity and liabilities					146.9		109.5		81.3
Cash flows from operating activities					(28.7)		(35.1)		(64.6)
Cash flows from investing activities					(0.5)		(0.4)		(0.4)
Of which investment in property, plant and equipment					(0.1)		(0.1)		(0.1)
Cash flows from financing activities					91.4		2.6		1.1
Net cash flows					62.1		(33.0)		(63.9)
Adjusted EBITDA	(17.1)		(14.5)		(32.4)		(30.2)		(61.9)
Revenue growth	29%		(2%)		23%		11%		5%
Gross profit percentage	71%		69%		67%		64%		62%
Equity ratio (solvency)	73%		70%		73%		70%		57%
Average number of employees	34		29		33		29		29
Number of shares at the end of the period (1,000)	334,693		267,754		334,693		267,754		267,754
Loss per share (EPS), DKK	(0.05)		(0.05)		(0.11)		(0.11)		(0.21)
Net asset value per share, period-end, DKK	0.32		0.29		0.32		0.29		0.17
Share price, period-end, DKK	1.22		3.16		1.22		3.16		2.47

Note: Loss per share (EPS) is calculated in accordance with IAS 33 “Earning per share”. Other financial ratios have been calculated in accordance with the guidelines from the Danish Society of Financial Analysts.

Reconciliation of Adjusted EBITDA
Loss before financial items (EBIT)	(20.1)		(14.5)		(38.4)		(32.7)		(65.3)
Depreciation and amortization	1.1		1.0		2.2		2.1		4.3
Share-based compensation expenses	1.9		(1.0)		3.8		0.4		(0.9)
Adjusted EBITDA	(17.1)		(14.5)		(32.4)		(30.2)		(61.9)

Non-IFRS Financial Measure

In the Interim Report, BioPorto discloses a financial measure of the Group’s financial performance that reflects adjustments to the most directly comparable measures calculated and presented in accordance with IFRS. This non-IFRS financial measure may not be defined and calculated by other companies in the same manner and may thus not be comparable.

The non-IFRS financial measure presented in the Interim Report is Adjusted earnings before interest, taxes, depreciation, and amortization (Adjusted EBITDA).

Adjusted EBITDA is an alternative measure of performance utilized by management, investors, and investment analysts to evaluate and analyze the Company’s results. Adjusted EBITDA excludes non-cash share-based compensation and non-recurring costs (e.g., merger and acquisition integration costs), if any. We believe that earnings exclusive of non-cash and non-recurring costs is a key indication of how a company is progressing from period to period and that the non-IFRS financial measure Adjusted EBITDA is useful to investors, lenders, and other creditors because such information enables them to better understand earnings exclusive of non-cash and non-recurring costs from period to period. However, we also believe that Adjusted EBITDA data has limitations, particularly as non-cash and non-recurring costs could significantly impact our performance. We therefore limit our use of Adjusted EBITDA and do not evaluate our results and performance without considering both non-IFRS Adjusted EBITDA on the one hand and net income or loss on the other. We caution the readers of this report to follow a similar approach by considering data on Adjusted EBITDA only in addition to, and not as a substitute for or superior to, net income or loss in accordance with IFRS.